Topiramate is an anticonvulsant and migraine drug that also reduces appetite and causes modest weight loss as a side effect. It is not independently FDA-approved for obesity — weight use is off-label — but it is a key component of the approved combination Qsymia (with phentermine). It carries cognitive, tingling and pregnancy-related cautions.
Obesity Medication Library entry. Section accent: family --teal.
DRUG FACT PANEL
| Generic | Topiramate |
| Brands | Topamax (also the neurostabiliser component of Qsymia — see phentermine/topiramate) |
| Class | Anticonvulsant / migraine-prophylaxis agent (multiple CNS mechanisms) |
| Mechanism (1 line) | Modulates neuronal excitability (sodium channels, GABA, glutamate, carbonic anhydrase); appetite suppression is a class effect |
| FDA indication | Epilepsy and migraine prophylaxis — not independently approved for weight loss; weight use is off-label except within Qsymia |
| Who it's for | Primarily a component of Qsymia for chronic weight management; standalone weight use is off-label and selective |
| Route/formulation | Oral, daily |
| Titration concept | Started low and increased slowly to limit cognitive and neurological effects — individual dosing is set by a clinician, not this page |
| Expected effect | Modest, dose-related weight loss as a standalone agent — below the GLP-1/dual-agonist drugs; its strongest weight evidence is as a component within the phentermine/topiramate combination (Qsymia) |
| Evidence level (obesity) | Grade C 🟠 as standalone/off-label; Grade B–A within Qsymia (see that page) |
What topiramate is
Topiramate is an anticonvulsant also approved for migraine prevention. Clinicians noticed years ago that patients lost weight on it, and that appetite-suppressing effect made it a candidate for obesity — first off-label, then formally as the neurostabiliser half of Qsymia (phentermine/topiramate). On its own it is not FDA-approved for weight loss; used for that purpose it is an off-label choice, most often when another indication (such as migraine) coexists with obesity. → Phentermine/Topiramate
How it works
Topiramate acts through several central mechanisms — modulating voltage-gated sodium channels, enhancing GABA activity, dampening glutamate signalling, and inhibiting carbonic anhydrase. How these translate into appetite suppression and reduced food intake is not fully mapped, but the effect is consistent across its uses. The carbonic-anhydrase action also explains some characteristic side effects (tingling, taste changes, kidney-stone risk). → Why Weight Is So Hard to Lose
What the trials actually show
The strongest weight-loss evidence for topiramate comes within the Qsymia combination, where phentermine and topiramate together produce more weight loss than either alone. As standalone therapy, the data are older and more limited, showing modest, dose-related weight loss — enough to be noticeable, but well below the level of the incretin drugs. Because its role in obesity is chiefly as the topiramate component of Qsymia, we describe its standalone effect qualitatively rather than quoting a monotherapy percentage. → Phentermine/Topiramate
Side effects
Common and distinctive: - Paresthesia — tingling in the hands, feet or face (a hallmark of the carbonic-anhydrase effect), often the first thing patients notice. - Cognitive effects — word-finding difficulty, slowed thinking, memory and concentration problems (sometimes nicknamed "dopamax"). Dose-related and a common reason for stopping. - Taste changes (especially carbonated drinks tasting flat), dizziness, fatigue, mood changes.
Less common / serious: kidney stones (carbonic-anhydrase effect), metabolic acidosis, acute angle-closure glaucoma (a specific ocular emergency), heat intolerance/reduced sweating, and teratogenicity (see below).
Contraindications & cautions
- Pregnancy — significant concern for cleft lip/palate and other harms; effective contraception is essential in people who can become pregnant (see below).
- Glaucoma — risk of acute angle-closure glaucoma.
- Kidney stones / metabolic acidosis history — caution.
- Cognitively demanding situations — the cognitive side effects can impair work or study.
- Abrupt discontinuation — taper rather than stop suddenly, particularly if used for seizures.
Monitoring, pregnancy and surgery
- Monitoring: cognitive and mood effects, paresthesia, hydration and stone symptoms; consider electrolytes/bicarbonate where relevant; eye symptoms warrant urgent attention.
- Pregnancy/lactation: teratogenic — associated with oral clefts and other risks. Reliable contraception is required in those who can become pregnant, and the drug should be discontinued if pregnancy is planned or confirmed. This is one of the most important cautions for topiramate and for Qsymia. → Women's Health & Obesity
- Perioperative: note the risk of metabolic acidosis and disclose use to the surgical team.
Long-term considerations, discontinuation and weight regain
For weight, topiramate treats a chronic condition and its appetite effect depends on continued use — stopping tends to be followed by regain. It should be tapered, not stopped abruptly (an anticonvulsant-class rule to avoid rebound/seizure risk). Cognitive side effects usually reverse after discontinuation. As with phentermine, durable weight management generally requires a longer-term plan, which is why the combination product exists. → Weight Regain & Maintenance
Unanswered questions
- Its best standalone role versus use only within Qsymia.
- How to predict who will get meaningful weight loss without limiting cognitive effects.
- Long-term safety of chronic use specifically for obesity.
Questions patients ask
Does topiramate cause weight loss?
Yes — it suppresses appetite and causes modest, dose-related weight loss as a side effect. But it's approved for epilepsy and migraine, not obesity, so weight use alone is off-label. Grade C 🟠
Why does it cause tingling?
The tingling (paresthesia) comes from its carbonic-anhydrase effect. It's common and usually harmless, though it leads some people to stop. Grade A 🟢
Will it affect my memory or thinking?
It can — word-finding trouble and slowed thinking are common, dose-related, and usually reverse after stopping. This is a frequent reason people discontinue. Grade A 🟢
Is topiramate safe in pregnancy?
No — it is teratogenic, associated with cleft lip/palate and other risks. Reliable contraception is essential, and it should be stopped if pregnancy is planned or confirmed. Grade A 🟢 → Women's Health & Obesity
Is this the same drug as in Qsymia?
Yes — Qsymia combines topiramate with phentermine, which produces more weight loss than either alone and is approved for chronic weight management. Grade A 🟢 → Phentermine/Topiramate
Can I just stop taking it?
It should be tapered, not stopped suddenly — abrupt discontinuation of an anticonvulsant can cause rebound effects. Cognitive side effects typically improve after stopping. Grade A 🟢
KEEP READING
- Phentermine/Topiramate (Qsymia) — the approved combination and its evidence.
- Obesity Medication Library — where topiramate sits among all options.
- Phentermine — the stimulant half of the combination.
- Women's Health & Obesity — teratogenicity and contraception in weight treatment.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: Topiramate FDA prescribing information (epilepsy/migraine); Qsymia program; pregnancy-registry data on oral clefts. Not individualized medical advice.
